pediatric cardiac transplantation present and future
play

Pediatric Cardiac Transplantation Present and Future Jeffrey - PDF document

Oct 11, 2022 •359 likes •496 views

Disclosure I have no relevant financial relationships with any companies related to the content of this course. Pediatric Cardiac Transplantation Present and Future Jeffrey Gossett, M.D., F.A.A.P. Director Heart Failure, Heart

  1. Disclosure  I have no relevant financial relationships with any companies related to the content of this course. Pediatric Cardiac Transplantation Present and Future Jeffrey Gossett, M.D., F.A.A.P. Director Heart Failure, Heart Transplantation Benioff Children’s Hospitals Objectives Objectives  To provide an overview of pediatric cardiac transplantation  To provide an overview of pediatric cardiac transplantation • What is the pediatric population that requires a OHT? • What is the pediatric population that requires a OHT? • How do they do? • How do they do?  Describe the changing face of congenital transplantation  • Shifting single ventricle population •  Discuss challenges of transplantation for failing Fontans  • Plastic bronchitis/ Protein losing enteropathy • • Early phase graft loss • 1 9/4/2018

  2. A nod to history So where have we come to? 700  First cardiac transplant: 11-17 600 • 12/3/1967: Christiaan Barnard - Cape Town 6-10 1-5 500  First infant cardiac transplant Number of Transplants <1 • 12/6/1967: Adrian Kantrowitz – Brooklyn 400 ‒ No immunosuppression 300  1984 Loma Linda – Baby Fae 200 • Managed with CSA – died POD #20  First successful Neonatal Transplant: November 15, 1985 100 • Leonard L. Bailey – Loma Linda, California 0 • Still alive as of 11/17 ISHLT Annual Report 2017; JHLT 2017 Oct; 36(10) 1037-1079 United States Who gets a transplant? 1988-2003 2009-6/2015 55% 73% < 1 year old 7% CHD 4% 1% 0.3% 38% 21% DCM 41% 40% 1 – 5 years old 11% Retransplant 9% 44% 3% 47% 4% Other 34% 35% 6 – 10 years old 15% 13% 44% 44% 9% 6% 26% 23% 11 – 18 years old 54% 58% 15% 11% 5% 8% United Network for Organ Sharing ISHLT Annual Report 2016; JHLT 2016 Oct; 35(10) 1149-1205 2 9/4/2018

  3. Patients Bridged with Mechanical Ventricular Assist Devices- Berlin Heart Circulatory Support 50  Para-corporeal VAD ECMO VAD + ECMO VAD or TAH  Pulsatile flow 40 ‒ Adults think we’re nuts! 34.8 32.9 % of Patients 29.4 29.7  Complication profile is not great 30 26.3 25.4 22.5 22.4 22.1 ‒ Neurologic concerns/strokes 21.3 20  But it’s what we got! 10 0 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 ISHLT Annual Report 2016; JHLT 2016 Oct; 35(10) 1149-1205 Pulsatile outcome (Berlin) Ventricular Assist Devices- Heartware  Intra-corporeal VAD • Continuous flow ‒ Standard of care for adults  Big two are Heartware (HVAD) and Heartmate II • Complication profile is dramatically better  But it’s gotta fit! • Almost for sure >40kg • Probably 20-40kg (been done down to ~15 kgs)  Discharge possible! http://www.uab.edu/medicine/intermacs/images/Federal_Quarterly_Report/Statistical _Summaries/Pedimacs_-_Federal_Partners_Report_2017_Q1.pdf 3 9/4/2018

  4. Continuous flow outcomes Outcomes- GRAFT Survival 1982-2015 100 <1 Year (N = 3,108) 1-5 Years (N = 2,934) 6-10 Years (N = 1,888) 75 11-17 Years (N = 5,065) Overall (N = 12,995) Survival (%) 50 25 Median survival (years): <1=22.3; 1-5=18.4; 6-10=14.4; 11-17=13.1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Years ISHLT Annual Report 2017; JHLT 2017 Oct; 36(10) 1037-1079 http://www.uab.edu/medicine/intermacs/images/Federal_Quarterly_Report/Statistical _Summaries/Pedimacs_-_Federal_Partners_Report_2017_Q1.pdf Outcomes– ERA effect Outcomes–2004-2015 conditional 100 100 1982-1989 (N=907) 1990-2003 (N=5,668) 2004-2008 (N=2,535) 2009-6/2015 (N=3,885) 90 75 Survival (%) Survival (%) 80 50 70 25 <1 Year (N = 1,168) 1-5 Years (N = 1,228) 60 Median survival (years):1982-1989= 9.8; 1990-2003=14.4; 6-10 Years (N = 791) 11-17 Years (N = 2,074) 2004-2008=NA; 2009-6/2015=NA Overall (N = 5,261) 0 50 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 0 1 2 3 4 5 6 7 8 9 10 11 Years Years ISHLT Annual Report 2017; JHLT 2017 Oct; 36(10) 1037-1079 ISHLT Annual Report 2017; JHLT 2017 Oct; 36(10) 1037-1079 4 9/4/2018

  5. Outcomes quality of life Objectives  100% • 80% •  Describe the changing face of congenital transplantation 60% • Shifting single ventricle population 40%  • 20% • No Activity Limitations Performs with Some Assistance Requires Total Assistance 0% 1 Year (N = 2,134) 5 Year (N = 1,415) 10 Year (N = 554) J Heart Lung Transplant 2008;27: 937-983 Congenital Heart Disease Congenital Heart Patients  This population is changing • Shift from early mortality ATS 2012; 94:807-16 JACC 2010 56(14):1149-57 5 9/4/2018

  6. Congenital Heart Patients Congenital Heart Patients 1986-1993 1986-1993 1994-2001 1994-2001 2002-2009 2002-2009 1986-1993 1986-1993 1994-2001 1994-2001 2002-2009 2002-2009 n=50 n=50 n=116 n=116 n=141 n=141 n=50 n=50 n=116 n=116 n=141 n=141 (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) Cardiomyopathy Cardiomyopathy 11/50 (22) 11/50 (22) 40/116 (34) 40/116 (34) 70/141 (49) 70/141 (49) Cardiomyopathy Cardiomyopathy 11/50 (22) 11/50 (22) 40/116 (34) 40/116 (34) 70/141 (49) 70/141 (49) CHD CHD 37/50 (74) 37/50 (74) 69/116 (60) 69/116 (60) 67/141 (48) 67/141 (48) CHD CHD 37/50 (74) 37/50 (74) 69/116 (60) 69/116 (60) 67/141 (48) 67/141 (48) Single V (% of CHD) Single V (% of CHD) Single V (% of CHD) Single V (% of CHD) Without palliation Without palliation 30/37 (81) 30/37 (81) 33/70 (47) 33/70 (47) 12/67 (18) 12/67 (18) After palliation After palliation 3/37 (8) 3/37 (8) 9/70 (13) 9/70 (13) 16/67 (24) 16/67 (24) Without palliation Without palliation 30/37 (81) 30/37 (81) 33/70 (47) 33/70 (47) 12/67 (18) 12/67 (18) After failed Fontan After failed Fontan 1/37 (3) 1/37 (3) 9/70 (13) 9/70 (13) 23/67 (34) 23/67 (34) After palliation After palliation 3/37 (8) 3/37 (8) 9/70 (13) 9/70 (13) 16/67 (24) 16/67 (24) Biventricular CHD Biventricular CHD 3/37 (8) 3/37 (8) 17/70 (24) 17/70 (24) 15/67 (22) 15/67 (22) After failed Fontan 1/37 (3) 9/70 (13) 23/67 (34) After failed Fontan 1/37 (3) 9/70 (13) 23/67 (34) Redo transplant Redo transplant 2/50 (4) 2/50 (4) 7/116 (6) 7/116 (6) 4/141 (3) 4/141 (3) Biventricular CHD Biventricular CHD 3/37 (8) 3/37 (8) 17/70 (24) 17/70 (24) 15/67 (22) 15/67 (22)  Shift away from primary transplant for HLHS/single ventricle Redo transplant Redo transplant 2/50 (4) 2/50 (4) 7/116 (6) 7/116 (6) 4/141 (3) 4/141 (3)  Increasing incidence of cardiomyopathy?? ‒ “Transplantation for heart failure related to failed SV palliation has become the most common indication for patients with CHD” ATS 2012; 94:807-16 ATS 2012; 94:807-16 Shifting Single Ventricles Future of OHT???  1986-93: 30/37 without palliation  If we add most of the neonatal palliations back later • 81 % of CHD and 60% of TOTAL transplant volume! 1986-1993 1986-1993 1994-2001 1994-2001 2002-2009 2002-2009 THE FUTURE?? THE FUTURE?? n=50 n=50 n=116 n=116 n=141 n=141 1986-1993 1994-2001 2002-2009 1986-1993 1994-2001 2002-2009 N=171 N=171 n=22 n=90 n=141 (%) (%) (%) (%) (%) (%) (%) (%) n=50 n=116 n=141 (%) (%) (%) (%) (%) (%) Cardiomyopathy Cardiomyopathy 11/50 (22) 11/50 (22) 40/116 (34) 40/116 (34) 70/141 (49) 70/141 (49) 70/171 (40) 70/171 (40) Cardiomyopathy 22 34 49 Cardiomyopathy 50 44 49 CHD 74 60 48 CHD 41 48 48 CHD CHD 37/50 (74) 37/50 (74) 69/116 (60) 69/116 (60) 67/141 (48) 67/141 (48) 95/171 (56) 95/171 (56) Single V (% of CHD) Single V (% of CHD) Single V (% of CHD) Single V (% of CHD) Without palliation 81 47 18 Without palliation 22 16 18 Without palliation Without palliation 30/37 (81) 30/37 (81) 33/70 (47) 33/70 (47) 12/67 (18) 12/67 (18) 12/95 (13) 12/95 (13) After palliation 33 21 24 After palliation 8 13 24 After failed Fontan 3 13 34 After failed Fontan 11 21 34 After palliation After palliation 3/37 (8) 3/37 (8) 9/70 (13) 9/70 (13) 16/67 (24) 16/67 (24) 16/95 (17) 16/95 (17) Biventricular CHD 8 24 22 Biventricular CHD 33 40 22 After failed Fontan After failed Fontan 1/37 (3) 1/37 (3) 9/70 (13) 9/70 (13) 23/67 (34) 23/67 (34) 51/95 (54) 51/95 (54) Biventricular CHD Biventricular CHD 3/37 (8) 3/37 (8) 17/70 (24) 17/70 (24) 15/67 (22) 15/67 (22) 15/95 (16) 15/95 (16) • So what happens if we take OUT most of those early HLHS? 6 9/4/2018

  7. Future of OHT?? Present of OHT!  Just focusing on the single ventricles then: Objectives The “Failed Fontan”   Uni-ventricular heart with “heart failure” ‒ Different from “typical” adult heart failure •  Ventricular dysfunction (or NOT) •  AV valve regurg   Arrhythmia •  Hepatic insufficiency  Discuss challenges of transplantation for failing Fontans  Protein losing enteropathy (PLE) • Plastic bronchitis/ Protein losing enteropathy  Plastic Bronchitis (PB) • Early phase graft loss • They just DON’T fit a box in UNet! 7 9/4/2018

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

We Can But Should We ? The Ethics of Pediatric Kidney Transplantation Robert Sibbald MSc

We Can But Should We ? The Ethics of Pediatric Kidney Transplantation Robert Sibbald MSc

We Can But Should We ? The Ethics of Pediatric Kidney Transplantation Robert Sibbald MSc (Clinical Ethicist- LHSC) Andrew Mantulak PhD RSW (Assistant Professor KUC) Whats in a talk In the spirit of social work week (our lens)

377 views • 34 slides
20 years of the Cardiac Care Network in Ontario: Past, Present and Future National Healthcare

20 years of the Cardiac Care Network in Ontario: Past, Present and Future National Healthcare

20 years of the Cardiac Care Network in Ontario: Past, Present and Future National Healthcare Leadership Conference Winnipeg Convention Centre, Winnipeg June 8, 2010 DISCLOSURE I do not have any current relationships with members of the

668 views • 29 slides
Lung Transplantation For Pediatric Pulmonary Hypertension No conflicts of interests No

Lung Transplantation For Pediatric Pulmonary Hypertension No conflicts of interests No

4/20/2018 Conflicts &amp; Disclosures Lung Transplantation For Pediatric Pulmonary Hypertension No conflicts of interests No relevant disclosures Funding Don Hayes, Jr., MD, MS, MEd Nationwide Childrens Hospital Cystic

352 views • 7 slides
3/12/2019 Cardiac Cath Why Bother? Cardiac Catheterization in Respiratory Status Preterm

3/12/2019 Cardiac Cath Why Bother? Cardiac Catheterization in Respiratory Status Preterm

3/12/2019 Cardiac Cath Why Bother? Cardiac Catheterization in Respiratory Status Preterm Infants with ventilatory settings, blood gases, chest CT UCSF Chronic Pulmonary Cardiac Status Pediatric Pulmonary Hypertension Program

543 views • 3 slides
May 6, 2016 1 https://www.youtube.com/watch?v=sff0_njY_lQ 5 POMA 108 th Annual Clinical Assembly

May 6, 2016 1 https://www.youtube.com/watch?v=sff0_njY_lQ 5 POMA 108 th Annual Clinical Assembly

Pediatric Cardiac Emergencies Ronald Wong, D.O. Pediatric Cardiac Emergencies Dr. Ronald Wong, DO Pennsylvania Osteopathic Medical Associations 108 th Annual Clinical Assembly May 6, 2016 1

542 views • 15 slides
Big data in the Cardiac ICU What can CNN can do for you? Kevin Maher, MD Professor

Big data in the Cardiac ICU What can CNN can do for you? Kevin Maher, MD Professor

Big data in the Cardiac ICU What can CNN can do for you? Kevin Maher, MD Professor of Pediatrics, Emory University School of Medicine Director, Cardiac Intensive Care, Childrens Healthcare of Atlanta Medical Director, Pediatric

838 views • 51 slides
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang

Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang

Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine, China Contents Introduction

774 views • 64 slides
The Future of Cardiac Devices: New devices, indications and ways to use Jeff Healey MD, MSc, FHRS

The Future of Cardiac Devices: New devices, indications and ways to use Jeff Healey MD, MSc, FHRS

The Future of Cardiac Devices: New devices, indications and ways to use Jeff Healey MD, MSc, FHRS Director of Arrhythmia Service PHRI Chair in Cardiology Research McMaster University Evolution of Cardiac Device Therapy Better cardiac

365 views • 19 slides
SUDDEN CARDIAC DEATH IN YOUNG ATHLETES Can the Cardiac Pre-participation Examination Save Lives?

SUDDEN CARDIAC DEATH IN YOUNG ATHLETES Can the Cardiac Pre-participation Examination Save Lives?

SUDDEN CARDIAC DEATH IN YOUNG ATHLETES Can the Cardiac Pre-participation Examination Save Lives? Joel Brenner, MD Director, Pediatric Cardiology Johns Hopkins Hospital Wall S treet Journal, 6/ 23/ 05 Sudden Cardiovascular Death During

582 views • 55 slides
Tolerance in transplantation David Berglund, MD/PhD Docent of Immunology Disclosure Consult

Tolerance in transplantation David Berglund, MD/PhD Docent of Immunology Disclosure Consult

Tolerance in transplantation David Berglund, MD/PhD Docent of Immunology Disclosure Consult for a start-up developing a monoclonal CD2 antibody for use in transplantation. Transplant tolerance History Present knowledge

738 views • 20 slides
My Heart Will Go On: Determination of Death, Organ Donation and Transplantation in Children

My Heart Will Go On: Determination of Death, Organ Donation and Transplantation in Children

My Heart Will Go On: Determination of Death, Organ Donation and Transplantation in Children Mudit Mathur, MD, MBA, FAAP, FCCM Director Pediatric Critical Care, Kaiser Permanente Associate Professor of Pediatrics, Loma Linda University

791 views • 68 slides
Strokes After TAVR Multi-factorial Origin, Incidence (past and present), and Management

Strokes After TAVR Multi-factorial Origin, Incidence (past and present), and Management

Strokes After TAVR Multi-factorial Origin, Incidence (past and present), and Management Considerations (present and future) Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Cleveland Clinic Conflict

710 views • 42 slides
1 Histology EARLY Lymphocytic Infiltrate GRANULOMA PHASE Diagnosis LATE - SCAR Favora et.

1 Histology EARLY Lymphocytic Infiltrate GRANULOMA PHASE Diagnosis LATE - SCAR Favora et.

Outline 1. Basics of Cardiac Sarcoidosis 2. Diagnosis of Cardiac Sarcoidosis Evaluation and Management of 3. Management of Cardiac Sarcoidosis Patients with Suspected Cardiac 4. Ventricular Arrhythmia in Cardiac Sarccoidosis Sarcoidosis 2016

408 views • 13 slides
NEURONAL TRANSPLANTATION AND ITS IMPLICATIONS IN PARKINSONS DISEASE 1. INTRODUCTION 2.

NEURONAL TRANSPLANTATION AND ITS IMPLICATIONS IN PARKINSONS DISEASE 1. INTRODUCTION 2.

NEURONAL TRANSPLANTATION AND ITS IMPLICATIONS IN PARKINSONS DISEASE 1. INTRODUCTION 2. ESSENTIAL ELEMENTS OF NEURONAL TRANSPLANTATION 3. CELL TYPES AND METHODS OF NEURONAL TRANSPLANTATION 4. NEURONAL TRANSPLANTATION IN ANIMAL MODELS OF PD

536 views • 16 slides
Present and Future Present and Future Supercomputer Architectures Supercomputer Architectures

Present and Future Present and Future Supercomputer Architectures Supercomputer Architectures

Hong Kong, China, 13-15 Dec. 2004 Present and Future Present and Future Supercomputer Architectures Supercomputer Architectures Jack Dongarra University of Tennessee and Oak Ridge National Laboratory 12/12/2004 1 A Growth- A Growth

526 views • 17 slides
2/17/14 Significant Drug Interactions in Hematopoietic Stem Cell Transplantation Cathryn

2/17/14 Significant Drug Interactions in Hematopoietic Stem Cell Transplantation Cathryn

2/17/14 Significant Drug Interactions in Hematopoietic Stem Cell Transplantation Cathryn Jennissen, PharmD, BCOP Pediatric Clinical Pharmacist Hematology/Oncology/Hematopoietic Stem Cell Transplant University of Minnesota Amplatz Children's

646 views • 18 slides
A Strategic Theory of Network Status Brian Rogers MEDS, Northwestern University July 10, 2008

A Strategic Theory of Network Status Brian Rogers MEDS, Northwestern University July 10, 2008

A Strategic Theory of Network Status Brian Rogers MEDS, Northwestern University July 10, 2008 SIAM 2008 Mini-Symposium 1 Motivation Why study social networks? Many kinds of complex relationships Reputation systems Research

4.61k views • 32 slides
Community Identification of Complex Network Xiang-Sun Zhang http://zhangroup.aporc.org Chinese

Community Identification of Complex Network Xiang-Sun Zhang http://zhangroup.aporc.org Chinese

Community Identification of Complex Network Xiang-Sun Zhang http://zhangroup.aporc.org Chinese Academy of Sciences 2008.10.31, OSB2008 1 Outline Background Community identification definition Community identification methods

658 views • 40 slides
Dark matter distribution Large and small scale structure Shinichiro Ando GRAPPA, University

Dark matter distribution Large and small scale structure Shinichiro Ando GRAPPA, University

Topical Lectures on DM@Nikhef 13 December 2017 Dark matter distribution Large and small scale structure Shinichiro Ando GRAPPA, University of Amsterdam Evidence for dark matter: Rotation curves v 2 = GM ( &lt; r ) r Inferring enclosed

525 views • 28 slides
An Indexed Central Limit Theorem Bob Lowen (with B. Berckmoes, J. Van Casteren) University of

An Indexed Central Limit Theorem Bob Lowen (with B. Berckmoes, J. Van Casteren) University of

An Indexed Central Limit Theorem An Indexed Central Limit Theorem Bob Lowen (with B. Berckmoes, J. Van Casteren) University of Antwerp Coimbra July 2012 Workshop on Category Theory in honour of George Janelidze on the occasion of his 60th

521 views • 40 slides
Stefan Anker, MD PhD Charit Medical School Berlin, Germany. CoI: Servier (speakers fees)

Stefan Anker, MD PhD Charit Medical School Berlin, Germany. CoI: Servier (speakers fees)

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT Commentary Stefan Anker, MD PhD Charit Medical School Berlin, Germany. CoI: Servier (speakers fees) Congratulations to the authors The

424 views • 10 slides
Life of a Performance Specialist Symposium on Software Performance (SSP 2015) Munich,

Life of a Performance Specialist Symposium on Software Performance (SSP 2015) Munich,

Into the wild Life of a Performance Specialist Symposium on Software Performance (SSP 2015) Munich, 5.-6.11.2015 Torsten Hellwig, Dipl.-Inf., Managing Partner @ QMETHODS Business &amp; IT Consulting GmbH 1 You dont need to walk to

345 views • 17 slides
STRUCTURAL PROOF THEORY: Uncovering capacities of the mathematical mind Wilfried Sieg Carnegie

STRUCTURAL PROOF THEORY: Uncovering capacities of the mathematical mind Wilfried Sieg Carnegie

STRUCTURAL PROOF THEORY: Uncovering capacities of the mathematical mind Wilfried Sieg Carnegie Mellon University Introduction . In one of his last published notes, Gdel claimed that Turing had committed a philosophical error in his paper

226 views • 11 slides
Social Facts, Patterns, and Marginality Professor Andrew J. Perrin Sociology 250 September 10,

Social Facts, Patterns, and Marginality Professor Andrew J. Perrin Sociology 250 September 10,

Social Facts, Patterns, and Marginality Professor Andrew J. Perrin Sociology 250 September 10, 2013 Sociology 250September 10, 2013 1 / Professor Andrew J. Perrin Social Facts, Patterns, and Marginality 18 Outline 1 du Bois and Durkheim,

926 views • 18 slides

More recommend